TargetBeta
IFNAR1
interferon alpha and beta receptor subunit 1 · also IFRC, IFNAR · Interferon receptors
5 programs in company-led studies act on IFNAR1, from 5 companies: 0 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| anifrolumabrule | AstraZeneca | phase 4 | 2512 running | – | ChEMBL |
| peginterferon alfa-2brule | Merck | phase 4 | 562 running | IFNAR2 | ChEMBL |
| peginterferon alfa-2arule | Hoffmann-La Roche | phase 4 | 1001 running | IFNAR2 | ChEMBL |
| Interferon beta-1arule | Biogen | phase 4 | 600 running | IFNA1, IFNAR2 | ChEMBL |
| SHR-2173 | Jiangsu HengRui Medicine | phase 2 | 86 running | TNFRSF13B | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Hepatitis B, Chronic, 2 programs
- Hepatitis C, 2 programs
- Hepatitis C, Chronic, 2 programs
- Lupus Erythematosus, Systemic, 2 programs
- Colitis, Ulcerative, 1 program
- COVID-19, 1 program
- Dermatomyositis, 1 program
- Glomerulonephritis, IGA, 1 program
- Glomerulonephritis, Membranous, 1 program
- Hepatitis B, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 6, 2027anifrolumab · AstraZeneca · phase 4 · NCT05925803
- Apr 2027SHR-2173 · Jiangsu HengRui Medicine · phase 2 · NCT07354932
- Apr 30, 2027peginterferon alfa-2a · Hoffmann-La Roche · phase 4 · NCT07389044
- May 31, 2029peginterferon alfa-2b · Merck · phase 4 · NCT06707922
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.